Milestone for Arana
Thursday, 02 October, 2008
Arana [ASX: ARA] has engineered an improved version of the VEGF-D antibody owned by Circadian Technologies [ASX: CIR] subsidiary Vegenics.
The antibody, designed to treat certain cancers, was modified into a humanised version using Arana's Superhumanisation technology.
It was then further refined using the company's EvoGene optimisation technology.
Conversion into humanised form will ensure that the risks of rejection of the treatment are minimised.
Circadian will shortly pay Arana milestone payments for the project, and Arana will be eligible to further milestone payments as the project advances through the various testing stages.
Sleep apnoea patients who use CPAP live longer: study
CPAP therapy has been found to significantly reduce the risk of death for people with obstructive...
Does exercise really extend lifespan? It's complicated
Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.